These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37160103)

  • 1. Meet the authors: Dr. Clint Allen and Dr. Sandro Santagata.
    Allen C; Santagata S
    Cancer Cell; 2023 May; 41(5):834-836. PubMed ID: 37160103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meet the authors: Daisuke Komura and Shumpei Ishikawa.
    Komura D; Ishikawa S
    Patterns (N Y); 2023 Jul; 4(7):100794. PubMed ID: 37521039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meet the authors: Dr. Eva Huber, Dr. Michael Groll, and Dr. Eric Ortlund.
    Huber E; Groll M; Ortlund E
    Structure; 2023 Jul; 31(7):762-763. PubMed ID: 37419100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meet the author: Professor Zhijian Cai.
    Cai Z
    Cell Metab; 2023 Aug; 35(8):1281-1282. PubMed ID: 37557069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tribute to Dr. Robert C. Allen, an inspirational teacher, humanitarian, and friend (Nov. 18, 1950-Mar. 24, 2005).
    Edlich RF; Greene JA; Long WB
    J Long Term Eff Med Implants; 2006; 16(3):261-4. PubMed ID: 17073568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
    Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M
    JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy.
    Yacyshyn MB; Poppema S; Berg A; MacLean GD; Reddish MA; Meikle A; Longenecker BM
    Int J Cancer; 1995 May; 61(4):470-4. PubMed ID: 7538976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
    Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
    PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA and cancer; computational and experimental approaches.
    Tutar Y
    Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8
    Yang B; Deng B; Jiao XD; Qin BD; Lu Y; Zhang W; Guo Y; Chen S; Li D; Li B; Zang YS
    Cell Oncol (Dordr); 2022 Dec; 45(6):1297-1309. PubMed ID: 36260222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction to: An update on the CNS manifestations of neurofibromatosis type 2.
    Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
    Acta Neuropathol; 2020 Apr; 139(4):667. PubMed ID: 31432207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
    Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
    Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lymphocyte activation markers in patients with ovarian cancer].
    Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
    Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR.
    Murray D; McMurray JL; Eldershaw S; Pearce H; Davies N; Scarisbrick JJ; Moss P
    Blood Adv; 2019 Feb; 3(4):519-530. PubMed ID: 30770361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
    Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of therapeutic potential of interleukin 2-expanded tumor-infiltrating lymphocytes in squamous cell carcinoma of the head and neck.
    Boscia R; Chen K; Johnson JT; Whiteside TL
    Ann Otol Rhinol Laryngol; 1988; 97(4 Pt 1):414-21. PubMed ID: 3261562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Journal Standards - Editor's reply.
    Jolly PD
    N Z Vet J; 2003 Aug; 51(4):199. PubMed ID: 16032326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
    Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Morishita Y; Kashiwabara K; Takazawa M; Ohara O; Kakimi K; Nakajima J
    J Thorac Oncol; 2017 May; 12(5):791-803. PubMed ID: 28088513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A medical journal editor's role in exposing an unethical research study.
    Jones RW
    Obstet Gynecol; 2009 Jan; 113(1):161-165. PubMed ID: 19104373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.